Skip to main content
Premium Trial:

Request an Annual Quote

Applied DNA Prices $12M Public Stock, Warrant Offering

NEW YORK — Applied DNA Sciences on Thursday priced a planned $12 million public offering of stock and warrants.

Through the offering, the Stony Brook, New York-based company will offer 3 million shares of its common stock, along with Series A and B warrants to purchase up to 6 million shares of common stock, at $4 per share and associated warrants. Both classes of warrants will be immediately exercisable at $4 apiece.

The offering is expected to close on or around Aug. 8.

Applied DNA, which earlier this year closed a roughly $4.2 million registered direct stock offering, said it will use the proceeds of the public offering to further the development of its therapeutic DNA production and molecular diagnostic testing services, as well as for general corporate purposes.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.